Division of Takeda Pharmaceutical Co. Ltd.
Latest From Inviragen Inc.
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.
While Sanofi late last year became the first company to commercialize a vaccine for dengue, Takeda has strengthened its position as the likely next to market contender following the start of a global Phase III program for its rival product.
Takeda has initiated dosing in the first field trial globally with a candidate vaccine for norovirus, maintaining its clear development lead in the area.
The China FDA has given a production nod to Beijing Sinovac for its EV71 vaccine, which now appears set to be the first product of its type globally to be commercialized. The company expects to launch the vaccine in June and is also actively seeking partners in other Asian countries.
- Therapeutic Areas
- Infectious & Viral Diseases
- InViragen LLC
- North America
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
Dan Stinchcomb, PhD, CEO
Jorge Osorio, PhD, CSO
Joseph Santangelo, PhD, COO
Gilad Gordon, MD, CMO
- Contact Info
Phone: (970) 672-4918
1613 Prospect Pkwy.
Fort Collins, CO 80525
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.